FDA Grants Fast Track Designation for Ambrx ’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the“Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials